<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1021/acs.inorgchem.9b02528</dc:identifier><dc:language>eng</dc:language><dc:creator>Abas, Elisa</dc:creator><dc:creator>Espallargas, Natalia</dc:creator><dc:creator>Burbello, Gianluca</dc:creator><dc:creator>Mesonero, José E.</dc:creator><dc:creator>Rodriguez-Dieguez, Antonio</dc:creator><dc:creator>Grasa, Laura</dc:creator><dc:creator>Laguna, Mariano</dc:creator><dc:title>Anticancer Activity of Alkynylgold(I) with P(NMe2)3 Phosphane in Mouse Colon Tumors and Human Colon Carcinoma Caco-2 Cell Line</dc:title><dc:identifier>ART-2019-115980</dc:identifier><dc:description>New alkynylgold(I) with P(NMe2)3 (HMPT) phosphane complexes, [Au(CC-R)(HMPT)] (R= 4-Ph, 4-MePh, 4-OMe, 4-Br, 4-Cl, 2-py, and 3-py) have been synthesized and characterized, including X-ray studies of complexes with R= 4-OMe and 4-Br; additionally, their physicochemical properties and anticancer activity have been tested. Due to the great water solubility of the HMPT phosphane, all the complexes exhibit an optimal balance of hydrophilicity/lipophilicity. Also, all of these complexes are quite stable in physiological conditions and interact well enough with the transport protein BSA. All complexes exhibit a higher anticancer activity against Caco-2 cells than cisplatin, and some of them do not present cytotoxic activity against enterocyte-like differentiated cells. The selective complexes are proapoptotic drugs by the exposure of phosphatidylserine, results that are also confirmed in primary cultures from mouse colon tumors. Complexes with a halogen unit also arrest the cell cycle in G2/M phase. It is thought that maybe these apoptosis processes are promoted by the observed oxidative damage in the membrane lipids, as a consequence of the inhibition of the thioredoxin reductase enzyme. Based on our results, we conclude that five of our complexes are good candidates to be used in chemotherapy.</dc:description><dc:date>2019</dc:date><dc:source>http://zaguan.unizar.es/record/129995</dc:source><dc:doi>10.1021/acs.inorgchem.9b02528</dc:doi><dc:identifier>http://zaguan.unizar.es/record/129995</dc:identifier><dc:identifier>oai:zaguan.unizar.es:129995</dc:identifier><dc:identifier.citation>Inorganic Chemistry 58, 22 (2019), 15536-15551</dc:identifier.citation><dc:rights>All rights reserved</dc:rights><dc:rights>http://www.europeana.eu/rights/rr-f/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>